SCHEMBL5408068

SCHEMBL5408068

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1NC(=O)Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ SYK P43405 2/20 0.43
▸ EGFR P00533 2/20 0.43
▸ TRPV1 Q8NER1 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ MAPK9 P45984 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ BTK Q06187 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ULK1 O75385 1/20 0.41
▸ NPY5R Q15761 1/20 0.41
▸ AURKA O14965 2/20 0.41
▸ STK17A Q9UEE5 2/20 0.41
▸ CTSC P53634 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416320 0.88 LRRK2 (0.47) LRRK2JAK2POLBSYKEGFR
SCHEMBL5418427 0.87 HDAC3 (0.47) LRRK2JAK2EGFRHDAC3HDAC1
SCHEMBL5409821 0.85 MEN1 (0.53) LRRK2JAK2EGFRBTKMEN1
SCHEMBL5413783 0.85 NPC1 (0.53) LRRK2JAK2EGFRHDAC3HDAC1
SCHEMBL5415421 0.84 STK17A (0.48) LRRK2JAK2SYKHDAC3HDAC1
SCHEMBL5418319 0.84 EGFR (0.45) LRRK2JAK2EGFRHDAC3HDAC1
SCHEMBL5415230 0.84 EGFR (0.48) SYKEGFRHDAC3HDAC1HDAC2
SCHEMBL5415948 0.83 HDAC3 (0.49) LRRK2JAK2POLBEGFRHDAC3
SCHEMBL5408198 0.82 HDAC3 (0.48) LRRK2JAK2SYKTRPV1HDAC3
SCHEMBL5413822 0.80 CYP3A4 (0.53) LRRK2JAK2SYKEGFRHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 LRRK2 619/4885JAK2 4450/4885POLB 1630/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 LRRK2 775/4885JAK2 4231/4885POLB 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback